MedTrace Logo

Prospective Study of VEGFR-2 /IL-8 Genetic Interaction in MBC Treated With Paclitaxel and Bevacizumab vs. Chemotherapy

NCT02329639 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 307

Last updated 2026-05-05

No results posted yet for this study

Summary

Metastatic Breast cancer (MBC) patients from ten Italian Divisions of Medical Oncology, with histologically confirmed HER2-negative MBC, treated with a first-line therapy including bevacizumab 10 mg/m2 i.v. on days 1 and 15 combined with first-line paclitaxel 90 mg/m2 i.v. on days 1,8 and 15, every 4 weeks, will be enrolled for the present pharmacogenetic study. MBC patients treated with first-line chemotherapy including paclitaxel without bevacizumab will be also enrolled as control group.

Conditions

Interventions

GENETIC

genetic interaction analysis

VEGFR-2 rs11133360/IL-8 rs4073 genetic interaction analysis

Sponsors & Collaborators

  • University of Pisa

    lead OTHER

Principal Investigators

  • Guido Bocci, MD, PhD · Dept. of Clinical and Experimental Medicine, University of Pisa

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2025-10-31
Completion
2026-04-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02329639 on ClinicalTrials.gov